A manufacturing problem flagged by U.S. regulators has halted a radiopharmaceutical, a cancer therapy that works by delivering radioactive isotopes directly to tumor cells. The drug's maker, ITM Isotope Technologies Munich SE, had already moved to commercialize it, launching a new division called Lumara Bio last month. The rejection blocks what would have been a new competitor for Novartis.
What the FDA found, and what it means
The agency's decision turned on manufacturing deficiencies, not the drug's clinical results. That distinction carries weight. A company that stumbles on manufacturing has a different corrective path than one whose efficacy data fell short, and that path remains open, in theory. No timeline for resubmission has been reported.
ITM had expected a different outcome. STAT reported the company had been anticipating FDA approval, which explains why Lumara Bio was already operational before any decision arrived. Lumara Bio was created specifically to commercialize and sell this therapy. Without a cleared product, the division has nothing to sell.
STAT describes ITM as a long-standing player in radiopharmaceuticals. The outlet characterizes the treatment category as emerging. Novartis already competes in this space, and ITM's drug would have been a direct challenger. The rejection removes that competitive pressure, at least for now.
Hims & Hers prepares a peptides push
The telehealth company Hims & Hers plans to enter the peptides market before the end of this year, Bloomberg News reported. Peptides, in this context, are compounds patients seek for wellness and longevity benefits. Clinical evidence supporting many of them remains limited.
Hims & Hers intends to sell compounds already permitted under current rules, rather than seeking new approvals. The plan arrives at a specific regulatory moment. The FDA is deciding whether to loosen restrictions on seven compounds, and last month it held a hearing in which outside advisers recommended easing production limits and expanding patient access. Those advisers do not bind the agency; their recommendation signals direction, not decision.
Bloomberg described the segment as a booming corner of the health industry. The FDA has not yet issued a final ruling on any of the seven compounds under review.